Schistosomiasis (bilharziasis) is a major cause of pulmonary arterial hypertension (PAH) worldwide. It is estimated that more than 5 to 20 million people suffer from the clinical manifestation of PAH because of the Schistosoma parasite. The majority is in sub-Saharan Africa. Unfortunately, this cause of PAH is the least studied. Schistosomiasis remains one of the most prevalent parasitic infections in the world. An estimated 240 million people are affected. Africa is the main affected area, followed by the Eastern Mediterranean region, South America, and Western Pacific regions. The condition is not present in Europe or North America (Figure 1). The disease is largely a rural problem, but urban foci can be found in many endemic areas. Even though control programs have had reasonable success in many parts of the world, the number of people estimated to be infected or at risk for infection has not been reduced. This is due at least in part to the fact that control is not universal because of econom-

Figure 1: Geographic distribution of schistosomiasis infection throughout the world. Bright red indicates severe endemic areas. Bubbles indicate factors that increase the infection rate and/or represent difficulties in control efforts.
ical and developmental projects and new irrigation programs that lead to a remarkable redistribution of schistosomiasis worldwide. Furthermore, there are reports of resistance to praziquantel, the mainstream medical treatment.6-9

The etiologic agents of schistosomiasis are blood flukes, which belong to the genus Schistosoma of the class of Trematoda of the phylum of Platyhelminthes (flatworms). The 3 most important species that affect humans are Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. There are several other species of lesser importance, which infect humans in Africa and Asia. Schistosoma is a white-greyish, cylindrical organism approximately 1 to 1.5 cm in length. It can survive for up to 20 to 40 years within human hosts. Schistosoma has separate sexes living in the blood vessels in a continuous, monogamous embrace, which produce thin-shelled eggs when excreted in feces or urine.

**LIFE CYCLE**

Understanding the Schistosoma life cycle (Figure 2) is essential for understanding the pathobiology of schistosomiasis and for disease control. Schistosoma eggs are excreted from the human host into a freshwater environment through urine or feces. When the eggs hatch, they release miracidium, which penetrates the freshwater snail intermediate host. They multiply asexually in the snail in a multilocular form called cercaria. The fork-tailed cercaria leaves the snail intermediate host prior to daytime light onto the water or up to 72 hours seeking the skin of a suitable definitive host.10 When they meet human skin or the skin of other mammalian hosts, the cercaria penetrate the skin by mechanical activity and via proteolytic enzymes. They travel via the venous or lymphatic vessels and migrate to the heart and lungs and then target their final organ location depending on the Schistosoma species (liver, bladder, or other organs). The females then start to produce hundreds to thousands of eggs per day.10 Half the number of eggs produced are excreted with feces or urine, while the rest remain in the tissues.

**PATHOLOGICAL AND IMMUNOLOGICAL REACTIONS**

Schistosoma eggs (with diverse antigens in their shells) are the main pathological agent. The host’s immune reaction to egg antigens evokes the formation of granulomatous inflammation around parasite eggs. This is a cardinal feature of schistosomiasis, and the egg-associated pathology is central to the morbidity and mortality that occurs in infected humans. Granulomas are dynamic structures of clustered inflammatory cells, including epithelioid and multinucleated giant cells, macrophages, monocytes, and T cells in addition to eosinophils and mast cells, with the proportion of cells differing in different organs.11 Activation of T cells in the granulomas (mainly CD4 and CD8 T cells) via both Th-1 and Th-2 responses are essential in the pathogenesis; this occurs predominantly via the release of inflammatory mediators like TNF-α, interferon-γ, interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, IL-23, IL-17, and resistin-like molecule (RELM)-α.12,13 Granulomas play an important role in destroying the ova; however, they also result in a fibrotic deposition in host tissue, which will cause the clinical manifestation of chronic schistosomiasis.14 The granuloma formation results in increased fibrosis and periporal collagen deposition, which leads to a gradual obstruction of blood flow in the targeted organ.14 For S. mansoni, for example, where the liver and spleen are the target organs, this will result in hepatosplenic enlargement, liver fibrosis, and portal hypertension.

**PATHOPHYSIOLOGY OF PULMONARY VASCULAR DISEASE DUE TO SCHISTOSOMIASIS**

Pulmonary vascular pathology invariably precedes pulmonary hypertension (PH) development in schistosomiasis. The portal hypertension-induced venous shunts between the portal and systemic circulation facilitate the passage of Schistosoma eggs from the liver to the lungs.15-18 Crosby et al19 noticed that levels of bone morphogenetic protein receptor II (BMPR2) modify the pulmonary vascular response to chronic schistosomiasis. BMPR2+/− mice demonstrated dilatation of the hepatic central vein at baseline and post infection, compared with wild type, suggesting increased passage of eggs to the lungs. The eggs trapped in the lungs can induce isolated granulomas within the alveolar area.20 In a study from our lab,21 in mice infected with schistosomiasis, the liver was a target during infection and was enlarged more than 2-fold after infection. We noticed that 92% of the lungs harvested from these animals showed...
evidence of granulomatous changes, secondary to egg deposition. However, the distribution of granulomatous lesions was heterogeneous. We also noticed remodeled pulmonary vessels in 46% of the lungs, but only near the granuloma. No remodeling was observed in the absence of granulomas, confirming the hypothesis that pulmonary vascular remodeling in PAH associated with schistosomiasis is caused by the local presence of granulomas. Others also observed a negative correlation between egg distance and degree of vascular remodeling. Thus density and distribution of egg deposition within the lung can influence the degree of remodeling and subsequently the development of pulmonary vascular disease and clinical manifestation of PAH. Histopathology of schistosomiasis-associated vascular diseases is similar to that of other forms of PAH, including occurrence of plexiform lesions. However, some unique features were observed in autopsy specimens. For example, a dark pigment is commonly seen adjacent to vascular lesions. The etiology of this pigment is not known, but may represent either debris left from the parasite or remnants of the host response. Whole ova surrounded by granulomatous inflammation are rarely seen.

The pathology of the remodeling process likely is inflammatory in nature. In our lab, we noticed a significant increase in the number of mast cells (toluidine blue+), CD3+ cells, CD14+ cells, CD68+ cells, and CD15+ cells in Schistosoma-infected tissues compared with untreated healthy controls. Others also noticed an increase in the density of dendritic CD83+ cells. These observations suggest that these cells may contribute to the pathophysiology of Schistosoma-induced pulmonary vascular remodeling. This is not surprising, as it is well documented that multiple inflammatory mediators induce pulmonary vascular remodeling in a variety of PH models. For example, IL-6 and IL-13 induce migration of pulmonary smooth muscle cells, thus contributing to pulmonary vascular remodeling. Transforming growth factor (TGF)-β signaling seems to be particularly important in driving vascular remodeling. It was also noticed that there is an increase in RELM-α expression within pulmonary granulomas of schistosomiasis-infected mice, similar to that seen in hypoxia models of PH, thus implicating this molecule as a mediator of the remodeling process. Other cytokines and mediators may also play a role.

THE PREVALENCE OF PH SECONDARY TO SCHISTOSOMIASIS

The exact prevalence of pulmonary vascular disease caused by Schistosoma infection is not known. The presence of Schistosoma eggs in the lungs of African natives was described as early as 1885. After that, several reports emerged from Egypt in the first half of the 20th century describing pathological and clinical manifestations of pulmonary vascular diseases secondary to infection by both S. mansoni and S. haematobium. In the second half of the 20th century, reports of many small series appeared in the literature, this time mainly from Brazil and occasionally a few cases from Africa, and more recently from China. In these studies, the prevalence ranged from 7.7% to 33%.

Recently, more carefully controlled methodological studies were conducted in patients with hepatosplenic schistosomiasis and liver fibrosis in Brazil, and results determined that 7.7% to 10.7% of patients were diagnosed with PH. It is, however, difficult to estimate the real prevalence of pulmonary vascular diseases worldwide, as this depends on many factors such as the geographical distribution, the public health status, differences in antigenicity and immune responses, and progress of the pathological changes. It is suggested from our experimental observations that the changes in the pulmonary vasculature after Schistosoma infection are far more common, but may not always be associated with significant increases in pulmonary vascular resistance or full clinical manifestations of PAH.

CLINICAL PRESENTATION OF SCHISTOSOMIASIS-INDUCED PAH

The pulmonary involvement of schistosomiasis can be as early as the first exposure to infection. Acute schistosomiasis (Katayama syndrome) is common in those infected with any Schistosoma species for the first time. Thus, this is commonly seen in nonimmune travelers or immigrants to Schistosoma-endemic regions. The early symptoms of acute schistosomiasis are usually nonspecific symptoms such as nocturnal fever, cough, dyspnea, myalgia, headache, and abdominal tenderness with eosinophilia, and lymphadenopathy. The condition can be resolved without morbidity consequences. On the other hand, chronic pulmonary disease is more common in endemic areas, but may not always produce any clinical symptoms. It is usually after repeated infections with a high antigenicity load of eggs that severe remodeling of the vessels produces PH with a significant increase in the pulmonary vascular resistance and consequently right heart failure. These patients generally present with signs and symptoms that are not distinguishable from other forms of PAH, such as dyspnea on exertion, anemia, fatigue, weakness, cough, dizziness, fainting, and exercise intolerance. Physical examination may reveal a prominent pulmonic component of the second heart sound and right ventricular heave and digital clubbing. Radiographs may reveal cardiomegaly, particularly dilatation of the right ventricle and right atrium, and enlarged pulmonary trunk and arteries, with pruning of the distal vasculature. It was demonstrated that pulmonary artery enlargement is more pronounced in schistosomiasis-induced PAH than an-
other form of PAH, suggesting that this is a more distinct feature of schistosomiasis-induced PAH (Figure 3).41-45 Electrocardiography may show right ventricular hypertrophy or strain and right atrial enlargement, and may also reveal a right bundle branch block. Echocardiography may demonstrate right ventricular dilatation, potentially compressing the left ventricle with septal bowing, usually accompanied by right atrial dilatation, tricuspid valve regurgitation, and an increased pressure gradient across the tricuspid valve as well as dilatation of the main pulmonary artery.

To assess causality, it is important to rule out other causes of PH. Patients in endemic areas should be suspect to have schistosomiasis as the cause of PH if they exhibit signs of prehepatic portal hypertension.9 We do not yet have biomarkers or serological tests to help in the diagnosis.46 It is, however, essential to perform right heart catheterization in order to provide a direct measurement of the mean pulmonary arterial pressure and to assess right ventricular function and pulmonary artery wedge pressure (PAWP). It is worth mentioning that about 13% of patients will also have compromised left ventricular function with an increase in PAWP.47 In addition, acute vasodilator challenge may be performed, but only a small number of patients exhibit a significant vasodilator response.48

TREATMENT OF SCHISTOSOMIASIS-INDUCED PAH
There are no clinical trials to confirm the application of any of the currently approved therapies for other types of PAH in schistosomiasis-PAH. Our current evidence is mainly observational from various centers all over the world. It has been conventional in many centers to treat these patients with the current modalities such as phosphodiesterase-5 inhibitors or endothelin receptor antagonists.49,50 Treatment with an anthelmintic drug, such as praziquantel, is warranted in cases of active schistosomiasis. This helps reduce the antigenic load, thus reducing the granulomata and probably preventing further deterioration.49 Interventions aimed at targeting inflammation, such as corticosteroids, may be useful, but it is uncertain whether they have any significant effect on the pulmonary vascular pathology. The prognosis of this condition has not been systematically studied. Initial small observations showed a more benign clinical course than in cases of idiopathic PH.48

References
1. Steinhann P, Keiser J, Bos R, Tanner M, Urzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis.* 2006;6(7):411-425.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380(9859):2163-2196.
3. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. *Lancet.* 2014;383(9936):2253-2264.
4. Mott KE, Desjeux P, Moncayo A, Ranque P, de Raadt P. Parasitic diseases and urban development. *Bull World Health Organ.* 1990;68(6):691-698.
5. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. *Acta Trop.* 2002;82(2):139-146.
6. Ross AG, Li Y, Williams GM, Jiang Z, McManus DP. Dam worms. *Biologist (London).* 2001;48(3):121-124.
7. Li YS, Sleigh AC, Ross AG, Williams GM, Tanner M, McManus DP. Epidemiology of Schistosoma japonicum in China: morbidity and strategies for control in the Dongting Lake region. *Int J Parasitol.* 2000;30(3):273-281.
8. McManus DP, Gray DJ, Li Y, et al. Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. *Clin Microbiol Rev.* 2010;23(2):442-466.
9. McManus DP, Gray DJ, Ross AG, Williams GM, He HB, Li YS. Schistosomiasis research in the dongting lake region and its impact on local and national treatment and control in China. *PLoS Negl Trop Dis.* 2011;5(8):e1053.
10. Gryseels B. Schistosomiasis. *Infec Dis Clin North Am.* 2012;26(2):383-397.
11. Almadi MA, Aljebream AM, Sanai FM, Marcus V, Almeghaiseeb ES, Ghosh S. New insights into gastrointestinal and hepatic granulomatous disorders. *Nut Rev Gastroenterol Hepatol.* 2011;8(8):455-466.
12. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. *Immunol Cell Biol.* 2007;85(2):103-111.
13. Chua C, Jones MK, Burke ML, McManus DP, Dobert GN. Cellular and chemokine-mediated regulation in schistosome-induced hepatic pathology. *Trends Parasitol.* 2014;30(3):141-150.
14. Peterson WP, Von Lichtenberg F. Studies on granuloma formation. IV. In vivo antigenicity of schistosome egg antigen in liver tissue. *J Immunol.* 1965;95(5):959-965.
15. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. *Chest.* 2010;137(Suppl):205-298.
16. Chaves E. The pathology of the arterial pulmonary vasculature in manson's schistosomiasis. *Dis Chest.* 1966;50(1):72-77.
17. de Clea R, Herman P, Pugliese V, Zilberstein B, Saad WA, Gama-Rodrigues JJ. Fathal pulmonary hypertension after distal splenorenal shunt in schistosomal portal hypertension. *World J Gastroenterol.* 2004;10(12):1836-1837.
18. Lamberti JR, Falcheto EB, Santos VA. Dilated paraumbilical vein in hepatosplenic schistosomiasis is associated with pulmonary hypertension. *Rev Soc Bras Med Trop.* 2013;46(6):797.
19. Crosby A, Soon E, Jones FM, et al. Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis. *Am J Respir Crit Care Med.* 2015;192(11):1355-1365.
20. Andrade ZA, Andrade SG. Pathogenesis of schistosomal pulmonary arteritis. *Am J Trop Med Hyg.* 1970;19(2):305-310.
21. Kolosionek E, King J, Rollinson D, et al. Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study. *Pulm Circ.* 2013;3(2):356-362.
22. Crosby A, Jones FM, Kolosionek E, et al. Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. *Am J Respir Crit Care Med.* 2011;184(4):467-473.
23. Crosby A, Jones FM, Southwood M, et al. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. *Am J Respir Crit Care Med.* 2010;181(3):279-288.
24. Wünschmann D, Ribas E. [Chronic cor pulmonale due to granulomatous and obliterating pulmonary arteritis caused by schistosomiasis]. *Zentralbl Allg Pathol.* 1989;135(3):241-247.
25. Sadigursky M, Andrade ZA. Pulmonary changes in schistosomal cor pulmonale. *Am J Med Hyg.* 1982;31(4):779-784.
26. Graham BB, Chabon J, Bandeira A, Espinheira L, Butrous G, Tuder RM. Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension. *Pulm Circ.* 2011;1(4):456-461.
27. Cohen-Kaminsky S, Hautefort A, Price L, Humbert M, Perros F. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. *Drug Discov Today.* 2014;19(8):1251-1256.
28. Mauad T, Pozzan G, Lanças T, et al. Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. *J Infect.* 2014;68(1):90-98.
29. Alfi Z, Kosanovic D, Kolosionek E, et al. Enhanced inflammatory cell profiles in schistosomiasis-induced pulmonary vascular remodelling. *Pulm Circ.* 2017; in press.
30. Tuder RM. Pulmonary vascular remodeling

Advances in Pulmonary Hypertension Volume 15, Number 3, 2017 147
in pulmonary hypertension. Cell Tissue Res. 2016 Dec 26. [Epub ahead of print]
31. Nicolls MR, Voelkel NF. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension. A Perspective. Am J Respir Crit Care Med. 2016 Oct 27. [Epub ahead of print]
32. Graham BB, Chabon J, Kumar R, et al. Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension. Am J Respir Cell Mol Biol. 2013;49(6):951-959.
33. Graham BB, Chabon J, Gebreab L, et al. Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation. 2013;128(12):1354-1364.
34. Kumar R, Mickael C, Chabon J, et al. The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension. Am J Respir Crit Care Med. 2015;192(8):998-1008.
35. Belleli V. Les oeufs de Bilharzia haematobia dans les poumons. Unione med. egiz., Alessandria. 1884-1885;1.
36. Shaw AFB, Ghareeb AA. The pathogenesis of pulmonary schistosomiasis in Egypt with special reference to Ayerza's disease. J Pathol Bacteriol. 1938;46:401-424.
37. Ward T, Butrous G, Fenwick A. The Prevalence of Pulmonary Hypertension in Schistosomiasis: A Systematic Review. PVRI Rev. 2011;3(1):12.
38. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation. 2009;119(11):1518-1523.
39. Lapa MS, Ferreira EV, Jardim C, Martins Bdo C, Arakaki JS, Souza R. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. Rev Assoc Med Bras. 2006;52(3):139-143.
40. Rocha RL, Pedroso ER, Rocha MO, Lambertucci JR, Greco DB, Ferreira CE. [Chronic pulmonary form of schistosomiasis mansoni. Clinico-radiologic evaluation]. Rev Soc Bras Med Trop. 1990;23(2):83-89.
41. Melrzer E, Artom G, Marva E, Assous M, Rahav G, Schwartz E. Schistosomiasis among travelers: new aspects of an old disease.Emerg Infect Dis. 2006;12(11):1696-1700.
42. Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis. 2007;7(3):218-224.
43. Hoette S, Figueiredo C, Dias B, et al. Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. BMC Pulm Med. 2015;15:118.
44. Abo-Salem ES, Ramadan MM. A huge thrombosed pulmonary artery aneurysm without pulmonary hypertension in a patient with hepatosplenic schistosomiasis. Am J Case Rep. 2015;16:140-145.
45. Santarém OL, Cleva Rd, Sasaya FM, et al. Left Ventricular Dilation and Pulmonary Vasodilatation after Surgical Shunt for Treatment of Pre-Sinusoidal Portal Hypertension. PLoS One. 2016;11(4):e0154011.
46. Kinkel HF, Dittrich S, Bäumer B, Weitzel T. Evaluation of eight serological tests for diagnosis of imported schistosomiasis. Clin Vaccine Immunol. 2012;19(6):948-953.
47. Ferreira RC, Domingues AL, Bandeira AP, et al. Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis. Ann Trop Med Parasitol. 2009;103(2):129-143.
48. dos Santos Fernandes CJ, Jardim CV, Hownanian A, et al. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol. 2010;56(9):715-720.
49. Loureiro R, Mendes A, Bandeira A, et al. Oral sildenafil improves functional status and cardiopulmonary hemodynamics in patients with severe pulmonary hypertension secondary to chronic pulmonary schistosomiasis: a cardiac magnetic resonance study. American Heart Association International Meeting. 2004;2569.
50. Fernandes CJ, Dias BA, Jardim CV, et al. The Role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. Chest. 2012;141(4):923-928.